secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001213900-26-047748
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis
--------------------------------------------------------------------------------

- Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.
- Rezafungin showed favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions.
- Target supplemental NDA submission to FDA in 2H26 based on ReSPECT results.
- CorMedix estimates US prophylaxis market opportunity for REZZAYO exceeds $2 billion.
- Mundipharma sponsored the trial; holds ex-US rights; Melinta (CorMedix sub) distributes in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/0001213900-26-047748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/ea0287640-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-047748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer